September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis
Author Affiliations & Notes
  • Szilard Kiss
    Physics & Astronomy/Sch of Optometry, Weill Cornell Medical College, New York, New York, United States
  • Yamina Rajput
    Genentech, Inc., South San Francisco, California, United States
  • Carlos Quezada Ruiz
    Genentech, Inc., South San Francisco, California, United States
  • Kathleen Wilson
    Truven Health Analytics, Bethesda, Maryland, United States
  • Alice Huang
    Truven Health Analytics, Bethesda, Maryland, United States
  • David M Smith
    Truven Health Analytics, Bethesda, Maryland, United States
  • Helen Varker
    Truven Health Analytics, Bethesda, Maryland, United States
  • Stephen S Johnston
    Truven Health Analytics, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Szilard Kiss, Alcon (C), Alimera (C), Allergan (C), Avalanche (C), B&L (C), Genentech-Roche (C), Regeneron (C); Yamina Rajput, Genentech (E); Carlos Quezada Ruiz, Genentech (E); Kathleen Wilson, Genentech (C); Alice Huang, Genentech (C); David Smith, Genentech (C); Helen Varker, Genentech (C); Stephen Johnston, Genentech (C)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3335. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Szilard Kiss, Yamina Rajput, Carlos Quezada Ruiz, Kathleen Wilson, Alice Huang, David M Smith, Helen Varker, Stephen S Johnston; Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3335.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the real-world treatment patterns, specifically, frequency and cost of intravitreal injections of two anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab (RBZ) and aflibercept (AFL), for treatment of wet age-related macular degeneration (AMD) in treatment-naïve (TN) and previously-treated (PT) patients over 2 years.

Methods : This retrospective US claims study included TN or PT patients who initiated RBZ or AFL treatment (index date [ID]) for AMD between 11-18-2011 and 7-31-2015. Patients were aged ≥18 years on the ID and were required to have continuous eligibility for 12 months (12M) prior to ID and for 12-24 months (24M) following ID without switching to another anti-VEGF agent. Injection frequency and cost for RBZ vs. AFL were compared at 12M and 24M using multivariable Poisson quasi-likelihood regressions (treating RBZ as reference) and multivariable generalized linear models with a log link and gamma distribution, respectively. All models were adjusted for patient demographics and clinical characteristics.

Results : Over 12M, TN AMD patients receiving RBZ (N=2260) and AFL (N=1256) had a comparable unadjusted mean number of injections (5.4 vs. 5.4, adjusted incidence rate ratio [IRR] = 0.99, 95% confidence interval [CI] = 0.95 to 1.03, P = 0.558) and marginally lower injection costs with AFL vs. RBZ ($10,417 vs. $11,032, adjusted cost ratio [CR] = 0.93, 95% CI = 0.89 to 0.98, P = 0.008). At 24M, injection frequency and cost were comparable between RBZ (N=1018) and AFL (N=482) in TN patients (7.6 vs. 8.1, IRR = 1.06, 95% CI = 0.98 to 1.14, P = 0.168; $15,393 vs. $15,410, CR = 0.99, 95% CI = 0.89 to 1.09, P = 0.832). Over 24M, PT AMD patients receiving RBZ (12M N=873; 24M N=344) or AFL (12M N=1990; 24M N=847) had comparable injection frequency (12M 5.7 vs. 5.8, IRR = 0.99, 95% CI = 0.96 to 1.04, P = 0.984; 24M 9.3 vs. 9.6, IRR = 1.00, 95% CI = 0.92 to 1.08, P = 0.926) and costs (12M $11,589 vs. $11,521, CR = 0.97, 95% CI = 0.92 to 1.03, P = 0.393; 24M $18,548 vs. $19,202, CR = 1.03, 95% CI = 0.92 to 1.14, P = 0.629).

Conclusions : This 2-year claims-based analysis shows that the real world treatment patterns for treatment-naïve and previously-treated patients, given RBZ or AFL for AMD, are comparable in costs and injection frequency.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×